Fennec Pharmaceuticals Inc(FENC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.13 | Insider Own | 14.17% | Shs Outstand | 35.0M | Perf Week | 1.59% |
| Market Cap | 0.36B | Forward P/E | 11.35 | EPS next Y | 217.61% | Insider Trans | -3.14% | Shs Float | 30.1M | Perf Month | -0.87% |
| Enterprise Value | 0.32B | PEG | - | EPS next Q | 0.1 | Inst Own | 56% | Short Float | 1.62% | Perf Quarter | 6.78% |
| Income | -0.00B | P/S | 6.06 | EPS this Y | 181.14% | Inst Trans | 1.1% | Short Ratio | 2.61 | Perf Half Y | 56.57% |
| Sales | 0.06B | P/B | 8.45 | EPS next 5Y | - | ROA | -5.98% | Short Interest | 0.49M | Perf YTD | 32.99% |
| Book/sh | 1.21 | P/C | 8.71 | EPS past 3/5Y | 27.71% 14.9% | ROE | -20.63% | 52W High | -22.72% ($13.25) | Perf Year | 22.93% |
| Cash/sh | 1.18 | P/FCF | - | Sales past 3/5Y | 207.52% 204.69% | ROIC | -8.5% | 52W Low | 81.24% ($5.65) | Perf 3Y | 48.84% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 70.59% | Gross Margin | 93.73% | Volatility(W/M) | 5.54% 5.13% | Perf 5Y | 10.58% |
| Dividend TTM | - | EV/Sales | 5.37 | Sales Y/Y TTM | 77.83% | Oper. Margin | -2.68% | ATR (14) | 0.54 | Perf 10Y | 409.45% |
| Dividend Ex-Date | - | Quick Ratio | 5.66 | EPS Q/Q | 147.59% | Profit Margin | -6.09% | RSI (14) | 45.49 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.85 | Sales Q/Q | 85.18% | SMA20 | -1.64% ($10.41) | Beta | 1.28 | Target Price | $17.2 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/11 | SMA50 | -6.35% ($10.93) | Rel Volume | 1.05 | Prev Close | $10.95 |
| Employees | 35 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 150% 10.29% | SMA200 | 11.23% ($9.21) | Avg Volume(3M) | 0.19M | Price | $10.24 |
| IPO | 2003/10/22 | Option/Short | Yes/Yes | Trades | 1938 | Volume | 195,661 | Change | -6.48% |
💊 Fennec Pharmaceuticals (FENC) is a U.S.-listed specialty pharmaceutical and biotech company built around a single core product, PEDMARK (sodium thiosulfate). PEDMARK is the first and only therapy of its kind approved in the United States to reduce the risk of hearing loss (ototoxicity) associated with cisplatin-based chemotherapy in pediatric patients with solid tumors. Leveraging its orphan drug exclusivity, the company is expanding its market presence in both the U.S. and Europe.
Over the past 1 year, roughly in the middle
23% below its 1-year high.
Traded about as much as usual. That is 105% of its average volume.
FENC has a sound balance sheet but weak earning power
Of every $100 in sales, $2.68 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +181.1% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $606. Peers typically go for $1,268.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +10.6%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 56.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #247 of 597 in the industry
Based on market cap of $359M.
AGMB#246 AgomAb Therapeutics NV ADR $369M PER - FENC#247 Fennec Pharmaceuticals Inc $359M PER - 
OBIO#248 Orchestra BioMed Holdings Inc $355M PER - 
CTNM#249 Contineum Therapeutics Inc $353M PER - 
KYTX#250 Kyverna Therapeutics Inc $351M PER - 
FAQ
What kind of company is FENC?
FENC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of FENC?
The market cap of FENC is approximately $359M, ranking 3,437 within its sector.
What is the 52-week high and low for FENC?
FENC has recorded a 52-week high of $13.25 and a low of $5.65.
